Intestinal inflammation in cystic fibrosis

Rosalind L Smyth*, Nicholas M Croft*, Una O’Hea, Tom G Marshall, Anne Ferguson

Abstract

Background—There is controversy about whether the inflammatory response observed in the cystic fibrosis (CF) lung occurs secondary to bacterial infection or is caused by a dysregulation of the inflammatory response associated with the basic cellular defect of CF.

Aims—to study the inflammatory response in the gastrointestinal tract of children with CF; and to investigate whether there is increased inflammation in the gastrointestinal tract of CF children with fibrosing colonopathy.

Methods—Whole gut lavage was performed on 21 pancreatic insufficient children with CF, who were clinically well, five children with CF and fibrosing colonopathy, and 12 controls. Intestinal outputs of plasma derived proteins (albumin, α1 antitrypsin, IgG), secretory immunoglobulins (IgA and IgM), cellular constituents (eosinophil cationic protein and neutrophil elastase), and cytokines (interleukin 8 and interleukin 1β) were measured.

Results—Compared to controls, the 21 CF children, with no intestinal complications, had increased intestinal outputs of albumin, IgG, IgM, eosinophil cationic protein, neutrophil elastase, interleukin 1β, and interleukin 8. Similar values were obtained for the CF patients with fibrosing colonopathy.

Conclusions—These data suggest that there is immune activation in the gastrointestinal mucosa of children with cystic fibrosis, which may result from the basic cellular defect. Fibrosing colonopathy does not appear to be associated with increased inflammation.


Keywords: mucosal immunity; cytokines; intestinal inflammation; whole gut lavage

The major cause of morbidity and death in cystic fibrosis (CF) patients relates to chronic bronchopulmonary infection which results in progressive bronchiectasis and eventually respiratory failure. An intense, neutrophil dominated inflammation of the airways is associated with the chronic infection and has generally been assumed to result from it. High concentrations of inflammatory markers have been reported in the blood of CF patients compared with controls and these correlated with measurements of disease severity. In the CF lung increased amounts of neutrophils, elastase, and cytokines have been reported in the bronchoalveolar lavage (BAL) fluid. These findings have been described, not only in CF patients with established lung disease and bronchiectasis, but in very young infants with minimal or no detectable lung disease. One group suggested that bacterial infection may initiate inflammation. Others suggested that inflammation is the initial event in the CF lung, causing damage and increasing susceptibility to infections. Thus there is currently controversy about whether the basic cellular defect in CF is associated with an inflammatory response per se, or whether the inflammatory response in the CF lung occurs secondary to bacterial infection.

We have investigated this question by studying the inflammatory response in CF in an organ other than the lung, the gastrointestinal tract. Whole gut lavage (WGL), which has been used in CF as a treatment of distal intestinal obstruction syndrome, results in a clear fluid (WGLF), essentially a gut perfusate. By administering the fluid to individuals at an equal rate, one can directly compare the concentrations of immune and inflammatory parameters in the resulting effluent. This has been used widely in clinical research in inflammatory bowel disease in both adults and children. As WGL is a gut perfusate with a steady state of output of proteins into the fluid, this allows estimation of the output of intestinal proteins from the mucosa of the whole gut.

We have previously undertaken a small study in CF children using WGL to investigate whether high strength pancreatic enzymes were associated with gut inflammation. We found evidence of gross inflammation in two children with distal intestinal obstruction syndrome. There were also small, but significant increases in the WGLF concentrations of albumin, interleukin 1 (IL-1), and IL-8 in children with CF. These raised parameters did not alter when five of the children were changed to low dose pancreatic supplements.

In this study we have extended this work to include more subjects and to look for evidence of inflammation in five children with fibrosing colonopathy. Instead of comparing the concentrations of proteins in the resulting lavage fluid, we have calculated the total intestinal outputs of proteins. This eliminates any possible errors that may be a consequence of individual children tolerating the administration of WGLF at different rates, which can affect the WGLF concentrations. Thus we are able to present the first directly measured intestinal outputs of proteins from gastrointestinal tracts of children and compare the results with published adult data. As secretory immunoglobulins (IgA and IgM) and eosinophil cationic protein (ECP) are thought to play major roles in the pathophysiology of CF,
Table 1  Daily intestinal output of proteins in whole gut lavage fluid from children with CF and controls

<table>
<thead>
<tr>
<th>Group</th>
<th>Substance</th>
<th>Median output (mg/kg/day)</th>
<th>Controls (n = 12)</th>
<th>CF patients (n = 21)</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predominantly plasma derived proteins</td>
<td>Albumin</td>
<td>2.5</td>
<td>8.3</td>
<td></td>
<td>0.0004</td>
</tr>
<tr>
<td></td>
<td>IgA</td>
<td>35.4 (n = 9)†</td>
<td>50.0 (n = 17)‡</td>
<td></td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>IgM</td>
<td>1.0</td>
<td>2.7 (n = 17)‡</td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>IL-6</td>
<td>3.6 (n = 9)‡</td>
<td>13.3</td>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>IL-8</td>
<td>0.0</td>
<td>64.5 (n = 16)</td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Secretory immunoglobulins</td>
<td>IgA</td>
<td>35.4 (n = 9)†</td>
<td>50.0 (n = 17)‡</td>
<td></td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>IgM</td>
<td>1.0</td>
<td>2.7 (n = 17)‡</td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>Albumin</td>
<td>2.5</td>
<td>8.3</td>
<td></td>
<td>0.0004</td>
</tr>
<tr>
<td></td>
<td>IgA</td>
<td>35.4 (n = 9)†</td>
<td>50.0 (n = 17)‡</td>
<td></td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>IgM</td>
<td>1.0</td>
<td>2.7 (n = 17)‡</td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>IL-6</td>
<td>3.6 (n = 9)‡</td>
<td>13.3</td>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>IL-8</td>
<td>0.0</td>
<td>64.5 (n = 16)</td>
<td></td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

*Mann–Whitney U test.
†Three specimens excluded for technical reasons.
‡Where there were insufficient specimens the exact number analysed is shown in brackets.

for this study, we added these to the panel of immune and inflammatory markers.

Methods

SUBJECTS

Whole gut lavage was performed electively on 26 pancreatic insufficient CF patients. Five of these were diagnosed as having fibrosing colonopathy. Three children had required surgical resection for fibrosing colonopathy at least one year prior to the WGL. One was diagnosed with fibrosing colonopathy some weeks after the WGL and subsequently required a right hemicolecetomy. The fifth had radiological appearances of fibrosing colonopathy, but did not require surgery. All five patients with a diagnosis of fibrosing colonopathy were receiving low dose pancreatic enzyme preparations at the time of the WGL. The remaining 21 children (median age 8.5 years, range 1.6–14.5) were receiving pancreatic enzyme supplements (12 receiving high dose preparations and nine low dose preparations). None of these 21 children had distal intestinal obstruction syndrome or any other abdominal pathology at the time of WGL. Twelve children were studied as immunologically normal controls (aged 11 months to 13 years). Eight had lavage for an essentially normal colonoscopy (one had a rectal polyp); in four it was performed to treat severe constipation.

The studies were performed in Edinburgh (13 patients and 12 controls), Liverpool (12 patients), and Leicester (one patient). The studies were approved by the Paediatrics/Reproductive Medicine Subcommittee of the Lothian Research Ethics Committee, the Liverpool Paediatric Research Ethics Committee, and the Leicestershire Ethics Committee.

Physiotherapy was performed before the WGL and any sputum was expectorated during the lavage. Following an overnight fast, a polyethylene glycol based electrolyte solution (Klean-Prep, Norgine, UK) was taken orally or administered by nasogastric tube or gastrostomy tube at a rate of approximately 15 ml/kg/h. The exact rate was recorded for each child as some children tolerated faster or slower rates better. The resulting effluent was collected once clear of all faecal material. Aliquots of this were collected, immediately processed with antibacterial and protease inhibitors, and stored in aliquots at −70°C.

MEASUREMENTS

Albumin and α1 antitrypsin (α1-AT) were assayed by immunoturbidimetric procedures, Enzyme linked immunosorbent assays (ELISAs), which had been developed in our laboratory were performed to assay IgA, IgG, and IgM. Commercially available kits were adapted to perform ELISAs for IL-8 (R&D Systems Inc., Minneapolis, USA) and IL-1β (Cistron, Biotechnology, New Jersey, USA). ECP was measured by radioimmunoassay (Kabi-Pharmacia, Uppsala, Sweden). Total neutrophil elastase was measured by an enzymatic technique as described previously. In order to calculate the output of the protein (per kg per day), the concentration (per ml) of lavage fluid was multiplied by the rate of lavage (ml per day) and divided by the weight of the child (kg).
DATA ANALYSIS

The data for the 21 pancreatic insufficient CF patients were aggregated and displayed as box (indicating interquartile ranges with medians in the boxes) and whisker (indicating ranges) plots. Data for the 12 control patients were displayed in a similar manner. Data for the three patients who had had surgery for fibrosing colonopathy and the two with fibrosing colonopathy who had not received surgery were shown separately as individual data points. Comparisons between the two groups of subjects (21 CF patients and 12 controls) were performed by the Mann–Whitney test. Probability values less than 0.05 were considered significant.

Results

Lavage procedures were successfully completed in 26 CF patients. A further four children were recruited to the study, but the WGL procedure was discontinued before the study was completed because the children complained of abdominal pain and distension and were finding it difficult to tolerate the ingestion of large volumes of the electrolyte solution. Table 1 and figs 1, 2, 3, and 4 summarise the results.

Compared with the control group, the CF patients had significantly increased concentrations of albumin, IgG, IgM, IL-1β, IL-8, neutrophil elastase, and ECP. There were no significant differences between the CF patients and controls for α1-AT and IgA. There was no significant difference between the median weight for age z scores of the 21 CF patients without fibrosing colonopathy and the controls. Because of the small numbers, we did not compare the patients with fibrosing colonopathy with either of the other two groups, but as shown in the figures, values obtained for

Figure 2  Intestinal output of cytokines in whole gut lavage fluid from children with CF and controls. Children with fibrosing colonopathy (FC) are shown by individual points. The box indicates the median and interquartile range, the whiskers are the whole range; p values are derived from the Mann–Whitney U test for non-parametric data. There were insufficient specimens for all the assays to be performed in all the children.

Figure 3  Intestinal output of cellular constituents in whole gut lavage fluid from children with CF and controls. Children with fibrosing colonopathy (FC) are shown by individual points. The box indicates the median and interquartile range, the whiskers are the whole range; p values are derived from the Mann–Whitney U test for non-parametric data. There were insufficient specimens for all the assays to be performed in all the children. NE, neutrophil elastase.

Figure 4  Intestinal output of secretory immunoglobulins in whole gut lavage fluid from children with CF and controls. Children with fibrosing colonopathy (FC) are shown by individual points. The box indicates the median and interquartile range, the whiskers are the whole range; p values are derived from the Mann–Whitney U test for non-parametric data. There were insufficient specimens for all the assays to be performed in all the children.
patients with fibrosing colonopathy generally fell within the normal CF patients' ranges. When we compared the 12 patients receiving high strength pancreatic enzyme preparations with the nine receiving low strength preparations, we found no significant differences in any of substances measured apart from IgM, which was higher in children taking high strength preparations (data not shown, \( p = 0.005 \)).

**Discussion**

We have shown increased intestinal outputs of plasma derived proteins (albumin and IgG), a secretory immunoglobulin (IgM), cellular constituents (ECP), and cytokines (IL-8 and IL-1\( \beta \)) in the WGLF of children with cystic fibrosis compared with disease free controls. We know that none of the children had significant gastrointestinal tract bleeding as the WGLF haemoglobin was not raised (data not shown). None of the inflammatory markers were increased in the five patients with a diagnosis of fibrosing colonopathy compared to CF patients without this condition. This indicates that, at the time these children were studied, there was no evidence of active inflammation in the gastrointestinal tract as a consequence of fibrosing colonopathy. However, three of these children had undergone surgical resection of the part of their colons likely to be most affected by fibrosing colonopathy. It is possible that fibrosing colonopathy may be the end result of a process of inflammation, which was no longer active at the time these children were studied. This study was not designed to address the question of whether CF patients receiving high dose pancreatic enzyme preparations had increased cytokines and other substances in WGL compared with CF patients receiving low strength preparations. Our previous study did not show any differences in concentrations of any substances measured in WGL in five children on high strength preparations who switched to low strength preparations and were studied again. We were only able to measure IgM in five of nine patients in the low strength group and it is possible that the increased IgM in WGL of children on high strength preparations was a spurious statistical finding.

Our data on intestinal output of proteins are the first published data in children. In adults, using a balloon perfusion system, total IgA secretion has been estimated to be approximately 40 mg/kg/day. This is very similar to our figure in control children (35.4 mg/kg/day) and that found in adult controls who have undergone WGL (32.5 mg/kg/day). WGL allows direct assessment of whole gut secretion, whereas in balloon perfusion systems it is necessary to make assumptions about the length of the bowel. By assessing output (rather than concentration) of proteins in a perfusion system, we have eliminated the need to measure dilution markers, which complicate the interpretation of similar techniques such as BAL. The use of such markers in BAL studies is controversial.

In studies which have used BAL to investigate airway inflammation in CF, increased concentrations of immunoglobulins, neutrophil elastase, IL-8, IL-1\( \beta \) and IL-1\( \beta \) have been found in the BAL of CF patients compared with controls. ECP has been found to be increased in the serum of CF patients compared with controls and the concentration of ECP was correlated with disease severity and poor pulmonary function. These studies have confirmed that inflammation in CF is not confined to the lungs, but is also present in the gastrointestinal tract.

Previous studies of mucosal inflammation in the gastrointestinal tract of CF patients have been very limited and we are the first group, to our knowledge, to investigate this using WGL. Using light microscopy, the presence of chronic inflammatory infiltration in the intestinal mucosa of some children with CF has been shown; however others have not shown significant abnormalities. Mairi et al studied duodenal and bronchial mucosa of CF patients and identified abnormally high DNA fragmentation and likely apoptosis compared to controls. They speculated that this was related to the lack of CFTR in the epithelial cells. Falchuk and Taussig showed increases in the number of IgA secreting plasma cells and in vitro secretion of IgA from biopsy specimens of the jejunum of children with cystic fibrosis. This did not correlate with Schwachman score, severity of lung disease, bacteria in sputum cultures, or serum IgA concentrations. These in vitro data suggest that increased IgA secretion is a consequence of increased local production of the immunoglobulin rather than alteration of the intraluminal environment. We have not shown significantly increased IgA output in our CF patients, possibly because of the relatively small numbers.

The discordance between the findings in the WGL for albumin (which was raised in the CF patients) and \( \alpha_1 \)-AT (which was not raised), is of interest, because stool \( \alpha_1 \)-AT is regarded as the best diagnostic test for protein losing enteropathy. As albumin is rapidly broken down in faecal material, whereas \( \alpha_1 \)-AT is not, measurement of stool \( \alpha_1 \)-AT is preferable to stool albumin. However, it is feasible that measurement of albumin using WGL would be a more sensitive diagnostic test for protein losing enteropathy.

Briars et al measured IL-8 and tumour necrosis factor \( \alpha \) in the faeces of CF patients. They found a negative correlation between faecal IL-8 concentrations and measures of pulmonary function and speculated that the source of these high concentrations of cytokines was from swallowed sputum. Increased concentrations of cytokines such as IL-8 are found in the sputum of patients with CF but we feel that cytokines we observed in the WGLF of children with CF were not solely derived from sputum for the following reasons. We have previously undertaken a study in CF children where IL-8 was assayed in the sputum and the weights of sputum which would have to be swallowed per hour to account for the amounts detected in lavage fluid were calculated. Calculated values ranged from 0.9 to 61 g per hour and four children, all with...
detectable IL-8 in WGLF, could not participate because they were unable to expectorate sputum. As part of this study, parents were asked to perform usual chest physiotherapy on the morning before lavage and to expectorate sputum during the procedure. This was to ensure that the amount of sputum swallowed during the test was kept to a minimum. It is possible that bacteria, or other contents of swallowed sputum may be involved in direct stimulation of the intestinal mucosa, but this would be impossible to address in vivo as it would require excluding sputum from the gastrointestinal tract for prolonged periods (days or weeks).

In this study we have not investigated the intestinal flora of the subjects and thus cannot be certain that the flora in the small bowel was normal. However, none of the children had any symptoms suggestive of bacterial overgrowth. Small bowel flora has previously been studied in CF patients and no abnormalities were found. Armstrong et al performed BAL in a group of CF infants with a mean age of less than 3 months, and found that lower respiratory tract infection was present in almost 40%. Total cell count and IL-8 concentrations were increased in these infants compared with uninfected CF infants and controls. They concluded that the inflammation occurred secondary to infection.

This view was challenged by the findings of two groups of investigators who performed BAL on infants with CF and found evidence of lung inflammation in the BAL in the absence of microbiological evidence of bacterial infection. These studies added weight to the hypothesis that the inflammatory component of CF lung disease may be initiated or at least amplified by the basic defect in CF.

This has been investigated further by both clinical and experimental studies in the lung and airway epithelia. Noah et al performed BAL studies in infants with and without CF. They measured cell counts and performed assays for a number of cytokines including IL-6, IL-8, and IL-10. They also cultured a variety of bacterial pathogens from both infants with CF and the non-CF controls. These included Moraxella catarrhalis, Staphylococcus aureus, and Haemophilus influenzae. They found that at a bacterial load, CF infants had higher concentrations of neutrophils and IL-8 compared with non-CF controls. This relation was found and also when a single pathogen, H influenzae, was examined.

Normal airway epithelial cells release IL-8 in response to neutrophil elastase, which is present in high concentrations in the respiratory epithelial lining fluid of CF patients. However there are likely to be mechanisms other than the influx of neutrophils operating to stimulate cytokine productions. Studies using CF bronchial epithelial cells have shown that excessive amounts of IL-6 and IL-8 are generated when the cells are stimulated with the proinflammatory cytokines tumour necrosis factor α or IL-1β. This response was potentiated by prior exposure of the cells to prostaglandin E2. Furthermore, in the murine CF model, studies of airway mucociliary clearance and inflammation have suggested that abnormalities in these parameters occur before infection of the airway. As with the lung, cystic fibrosis transmembrane regulator (CFTR) gene expression is relatively high in the small and large intestine, and is increased in mucosal epithelial cells that are near lymph nodes. There are a number of potential mechanisms by which abnormal CFTR function may lead to dysregulation of the inflammatory responses. Arachidonic acid, a precursor of proinflammatory lipid mediators, is released in abnormally high concentrations from epithelial cells expressing the deltaF508 mutation in CFTR. IL-10 is a regulatory cytokine which is known to suppress inflammation in the lung and is present in reduced concentrations in BAL fluid from CF patients. If this dysregulation of inflammatory response was related to absent or abnormal CFTR, it is biologically plausible that it should be present not only in the lungs, but in other organs where CFTR is expressed.

Our results provide important insights into the possible association between the basic defect of CF and inflammation. By studying the inflammatory response in an organ other than the lung, we have shown evidence of inflammation at a site where pathogenic bacterial colonisation and infection does not normally occur. We suggest that in an environment in which CFTR does not function normally, the inflammatory response is deranged; this may be related to the pathological effects observed in CF.

We thank Dr O’Callaghan, University of Leicester, for allowing us to include one of his patients in this study. This study was supported by a grant from Solvay Healthcare (UK) Ltd. NC was supported by the Allan Fellowship, Faculty of Medicine, University of Edinburgh.

Intestinal inflammation in cystic fibrosis


Intestinal inflammation in cystic fibrosis

Rosalind L Smyth, Nicholas M Croft, Una O'Hea, Tom G Marshall and Anne Ferguson

Arch Dis Child 2000 82: 394-399
doi: 10.1136/adc.82.5.394

Updated information and services can be found at:
http://adc.bmj.com/content/82/5/394

These include:

References
This article cites 34 articles, 10 of which you can access for free at:
http://adc.bmj.com/content/82/5/394#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (2018)
- Cystic fibrosis (182)
- Pancreas and biliary tract (269)
- Drugs: endocrine system (120)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/